AL-002

Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases.

Cassava Sciences' simufilam failed to reduce cognitive decline in a Phase III Alzheimer's trial, leading to the termination of a second study.

Alector's AL002, an anti-TREM2 antibody being developed with AbbVie, failed to meet the primary endpoint in the Phase II INVOKE-2 study for Alzheimer's disease.

Alector Therapeutics' AL002, an experimental antibody designed to activate microglia, failed to slow disease progression in a Phase 2 trial for early Alzheimer's disease.

Over 120 Alzheimer's Disease treatment therapies are under development globally, targeting various mechanisms of action and routes of administration.